This HTML5 document contains 126 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
rdfs	http://www.w3.org/2000/01/rdf-schema#
skos	http://www.w3.org/2004/02/skos/core#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n11	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
n8	http://dx.doi.org/10.1002/
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q39333338

rdf:type

wikibase:Item

schema:description

სამეცნიერო სტატია artykuł naukowy artigo científico 2013년 논문 мақолаи илмӣ vitskapeleg artikkel 2013年學術文章 научна статия 2013年学术文章 ২০১৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scienca artikolo artikull shkencor artigo científico (publicado na 2013) articol științific мақолаи илмӣ mokslinis straipsnis article científic 2013年學術文章 научни чланак videnskabelig artikel (udgivet 2013) vitenskapelig artikkel article scientific 2013年学术文章 tieteellinen artikkeli 2013 nî lūn-bûn مقالهٔ علمی naučni članak 2013年學術文章 artículu científicu espublizáu en 2013 bilimsel makale научная статья 2013年学术文章 artikulong pang-agham مقالة علمية نشرت بتاريخ 30-9-2013 artigo científico (publicado na 2013) سائنسی مضمون 2013年の論文 επιστημονικό άρθρο vedecký článok 2013年學術文章 наукова стаття, опублікована у вересні 2013 wetenschappelijk artikel գիտական հոդված artículo científico publicado en 2013 articolo scientifico научни чланак scientific article מאמר מדעי บทความทางวิทยาศาสตร์ 2013年學術文章 2013年学术文章 vetenskaplig artikel article scientifique (publié 2013) wissenschaftlicher Artikel 2013年學術文章 bài báo khoa học 2013年学术文章 tudományos cikk teaduslik artikkel vědecký článek

p:P577

wds:Q39333338-79716979-8CBB-4654-BBF9-12104AD79E04

wdt:P577

2013-09-30T00:00:00Z

p:P407

wds:Q39333338-F5EA9389-F829-4BE1-9E3E-77ABAA38D414

wdt:P407

wd:Q1860

p:P2860

wds:Q39333338-AC8E27E3-AB3B-4E46-AB1F-3E02A5BCA2D1 wds:Q39333338-EF134B99-AA1C-4EB9-83A8-425C5C992D3B wds:Q39333338-CD8F8EFD-C859-4350-B9E6-6FDB67EBB610 wds:Q39333338-2B2F6D70-28C1-4501-B6BA-3CCFE4DB44A5 wds:Q39333338-2CF92CC1-0C6E-4960-8545-93339BAED953 wds:Q39333338-30D99A06-1DAD-4D8D-8AF0-379DC6E65F93 wds:Q39333338-399E975D-2CAA-43C4-AC90-FEDBCD2AEC3A wds:Q39333338-6EA53804-0B5E-43FA-8A48-DCB71EDC39F0 wds:Q39333338-850217E0-D775-47B7-814A-5E609CDD14A5 wds:Q39333338-47C01951-75DE-4D91-A836-9C62A212D5C4 wds:Q39333338-6352A47E-9C20-4CC6-A193-34ECA9CACF53 wds:Q39333338-BB30873C-3405-4B65-8E46-D465FA58C866 wds:Q39333338-C58B44D1-957B-43DF-92F2-6E84011B4054 wds:Q39333338-90F652B6-8538-4D87-A371-8DFD6EA2AB9B wds:Q39333338-AC60F3D0-49DE-4DB5-80CF-F8A5B6DA9A10

wdt:P2860

wd:Q28305585 wd:Q52016073 wd:Q29615834 wd:Q56568485 wd:Q38026023 wd:Q42917171 wd:Q40987983 wd:Q28259134 wd:Q43756677 wd:Q29615678 wd:Q29614910 wd:Q25938989 wd:Q48858572 wd:Q35607214 wd:Q46063768

rdfs:label

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

skos:prefLabel

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

schema:name

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

p:P50

wds:Q39333338-E009C7EC-7138-4F74-A238-827AB8125F8A

wdt:P50

wd:Q98686625

p:P1476

wds:Q39333338-8302DBE0-A07C-4350-8F80-E775F440C726

wdt:P1476

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

p:P304

wds:Q39333338-1D3E8C03-F8D8-4B07-98AF-948E7CF7160F

wdt:P304

1823-1831

p:P31

wds:Q39333338-CC8F5887-F0BB-4448-9DEB-E57C04CB61E9

wdt:P31

wd:Q13442814

p:P921

wds:Q39333338-EA35C4C3-33C8-4AAE-A6AF-21083FBD5923

wdt:P921

wd:Q11085

p:P698

wds:Q39333338-D02F8852-60BA-4632-98BC-E316B47B445C

wdtn:P698

n11:24123224

wdt:P698

24123224

p:P1433

wds:Q39333338-98B59724-6877-4E44-93E5-BBBC5510A8BE

wdt:P1433

wd:Q1486418

p:P433

wds:Q39333338-523C266F-1A88-4B82-B4C6-CC077D134AB3

p:P478

wds:Q39333338-3A928E6A-950B-46AD-87E0-0C08EF63CC34

wdt:P433

13

wdt:P478

28

p:P356

wds:Q39333338-AEEA5FE9-FB80-4C50-B560-6EA5E55BFD3D

wdtn:P356

n8:MDS.25639

wdt:P356

10.1002/MDS.25639